MAM
MRNA icon

Meeder Asset Management’s Moderna MRNA Stock Holding History

Meeder Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.51K Sell
93
-130
-58% -$6.73K ﹤0.01% 792
2026
Q1 		$11.3K Buy
223
+86
+63% +$4.01K ﹤0.01% 668
2025
Q4 		$4.04K Sell
137
-1
-0.7% -$27 ﹤0.01% 822
2025
Q3 		$3.56K Buy
138
+31
+29% +$865 ﹤0.01% 724
2025
Q2 		$2.95K Buy
107
+25
+30% +$658 ﹤0.01% 779
2025
Q1 		$2.33K Sell
82
-30
-27% -$1.06K ﹤0.01% 858
2024
Q4 		$4.66K Buy
112
+12
+12% +$574 ﹤0.01% 841
2024
Q3 		$6.68K Buy
100
+8
+9% +$734 ﹤0.01% 696
2024
Q2 		$10.9K Sell
92
-6
-6% -$759 ﹤0.01% 632
2024
Q1 		$10.4K Buy
+98
New +$9.88K ﹤0.01% 544
2023
Q1 		– Sell
-29,802
Closed -$5.35M – 758
2022
Q4 		$5.35M Sell
29,802
-9,357
-24% -$1.53M 0.47% 46
2022
Q3 		$4.63M Buy
39,159
+9,986
+34% +$1.52M 0.27% 75
2022
Q2 		$4.17M Buy
29,173
+6,268
+27% +$896K 0.24% 81
2022
Q1 		$3.94M Buy
+22,905
New +$3.86M 0.19% 97
2021
Q4 		– Sell
-11,360
Closed -$4.37M – 1889
2021
Q3 		$4.37M Sell
11,360
-15,016
-57% -$5.54M 0.23% 96
2021
Q2 		$6.2M Buy
26,376
+1,437
+6% +$257K 0.29% 78
2021
Q1 		$3.27M Buy
24,939
+24,069
+2,767% +$3.49M 0.17% 125
2020
Q4 		$91K Sell
870
-10,231
-92% -$1.04M 0.02% 437
2020
Q3 		$785K Buy
11,101
+367
+3% +$25.6K 0.05% 276
2020
Q2 		$690K Sell
10,734
-2,924
-21% -$160K 0.04% 305
2020
Q1 		$409K Buy
13,658
+13,531
+10,654% +$311K 0.03% 384
2019
Q4 		$2K Buy
127
+7
+6% +$124 ﹤0.01% 2028
2019
Q3 		$2K Buy
+120
New +$1.77K ﹤0.01% 1968

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Meeder Asset Management's MRNA Position: Q2 2026 in Review

Meeder Asset Management reduced its Moderna (MRNA) stake by 58% in Q2 2026, selling an estimated $6.73K and leaving 93 shares worth $6.51K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

Meeder Asset Management first reported a position in MRNA in Q3 2019 and has held it in 23 quarters since. The position peaked at $6.2M in Q2 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Meeder Asset Management held 93 shares of Moderna worth $6.51K as of Q2 2026.
  • Meeder Asset Management sold 130 Moderna shares in Q2 2026, an estimated $6.73K.
  • Moderna made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #792 holding.
  • Meeder Asset Management first reported a position in Moderna in Q3 2019 and has held it in 23 quarters since.
  • Meeder Asset Management's Moderna position peaked at $6.2M in Q2 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.